Education
About Us
Working with TipRanks
Follow Us
Medifast (MED)
NYSE:MED
MED Stock Chart & Stats
$10.97
-$0.62(-3.78%)
At close: 4:00 PM EST
$10.97
-$0.62(-3.78%)
Day’s Range― - ―
52-Week Range$10.10 - $15.46
Previous CloseN/A
Volume160.90K
Average Volume (3M)229.79K
Market Cap
$114.75M
Enterprise Value$42.67M
Total Cash (Recent Filing)$167.27M
Total Debt (Recent Filing)$16.79M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
May 04, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding10,991,273
10 Day Avg. Volume293,610
30 Day Avg. Volume229,786
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue0.11
Enterprise Value/Gross Profit0.16
Enterprise Value/Ebitda29.35
Forecast
1Y Price Target
$12.00Price Target Upside9.39% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.61
Revenue Forecast (FY)$337.50M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Ample LiquidityA large cash balance and zero debt provide a durable financial runway to fund the product launch, restructuring and marketing investments without near-term financing risk. This preserves strategic optionality and lowers solvency risk while management executes a multi-quarter turnaround plan.
High Gross Margins With Clinical DifferentiationSustainably high gross margins indicate strong unit economics for meal and supplement products; clinical data supporting a metabolic-health positioning can defend pricing and drive differentiated demand over months, improving profit recovery as volumes normalize.
Material Cost Reductions And RestructuringSignificant, enacted cost reductions lower the revenue breakeven for profitability and extend cash runway. Structural SG&A cuts and coach compensation realignment improve operating leverage and make a return to positive EBITDA more achievable even if top-line recovery is gradual.
Bears Say
Multi-year Revenue Decline And 2025 LossSustained revenue contraction and a full-year loss reflect weakening demand and impaired operating leverage. Persistent top-line declines reduce scale benefits of the DTC plus coach model and make margin recovery and consistent free cash flow generation more challenging over the next several quarters.
Sharp Deterioration In Coach NetworkThe coach network is the company's core distribution and retention mechanism; a structural ~40% decline materially reduces recurring revenue and customer outreach. Recovery depends on reactivating or rebuilding the coach base, a multi‑month process vulnerable to ongoing GLP‑1 secular shifts.
Weak Cash Generation / Compressed Free Cash FlowSharply reduced operating cash flow and minimal free cash flow limit reinvestment capacity and increase reliance on the cash stockpile. Thin cash conversion heightens execution risk for product launches and marketing, and reduces buffer against further demand shocks over the coming quarters.
Medifast News
MED FAQ
What was Medifast’s price range in the past 12 months?
Medifast lowest stock price was $10.10 and its highest was $15.46 in the past 12 months.
What is Medifast’s market cap?
Medifast’s market cap is $114.75M.
When is Medifast’s upcoming earnings report date?
Medifast’s upcoming earnings report date is May 04, 2026 which is in 61 days.
How were Medifast’s earnings last quarter?
Medifast released its earnings results on Feb 17, 2026. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.82 by $0.27.
Is Medifast overvalued?
According to Wall Street analysts Medifast’s price is currently Undervalued.
Does Medifast pay dividends?
Medifast pays a Quarterly dividend of $1.65 which represents an annual dividend yield of N/A. See more information on Medifast dividends here
What is Medifast’s EPS estimate?
Medifast’s EPS estimate is -0.52.
How many shares outstanding does Medifast have?
Medifast has 10,991,273 shares outstanding.
What happened to Medifast’s price movement after its last earnings report?
Medifast reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.82. Following the earnings report the stock price went down -0.833%.
Which hedge fund is a major shareholder of Medifast?
Currently, no hedge funds are holding shares in MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (9.39% Upside)
$12.00 (9.39% Upside)
Blogger Sentiment
Bullish
MED Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 294.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.29%
12-Months-Change
Fundamentals
Return on Equity
-9.13%
Trailing 12-Months
Asset Growth
-12.35%
Trailing 12-Months
Company Description
Medifast
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of encouraging operational and strategic early signs (positive coach productivity inflection, stronger coach leadership metrics, clinical validation of the metabolic health positioning, meaningful cost reductions and a strong cash position) alongside significant near-term financial challenges (large YoY revenue decline, a ~41% drop in active earning coaches, compressed gross profit and an $18.1M net loss driven in part by a $12.1M deferred tax valuation allowance). Management provided full-year guidance and a path toward returning to profitability in late 2026, but the magnitude of recent declines and the ongoing market disruption from GLP-1 adoption imply substantial execution risk before recovery is evident in top-line results.View all MED earnings summariesMED Stock 12 Month Forecast
Average Price Target
$12.00
▲(9.39% Upside)
Technical Analysis
Ownership Overview
4.71% Insiders
14.47% Mutual Funds
5.00% Other Institutional Investors
54.30% Public Companies and
Individual Investors